Ionis to hold first quarter 2024 financial results webcast
Ionis Pharmaceuticals Inc IONS
News
-
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
Ionis to present at upcoming investor conferences
Ionis to hold olezarsen Phase 3 data webcast
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
Ionis announces new chief global product strategy officer to lead next phase of commercial growth
Ionis to present at upcoming investor conferences
Ionis reports fourth quarter and full year 2023 financial results
Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome
Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
Ionis to hold fourth quarter and full year 2023 financial results webcast
Ionis Pharmaceuticals, AstraZeneca get FDA approval for rare genetic disease treatment
Ionis Pharmaceuticals, AstraZeneca Get FDA Approval for Rare Genetic Disease Treatment
Ionis, Roche Set New Pact Targeting Alzheimer's, Huntington's
Biogen wins accelerated FDA approval for treatment for rare form of ALS
Wall Street analysts predict approval for another ALS drug